Abstract:Abstract Background: Increasing the immunogenicity of solid tumors may potentiate durable anti-tumor immunity. Targeting innate pattern recognition receptor signaling is a promising strategy to repolarizing the suppressive tumor immune microenvironment (TME). A potential synergistic approach is the addition of cellular therapy. Tumor models expressing high levels of endogenous STING, but where the pathway is not active, were considered for evaluating STING agonism as a potential intervention. Additionally, prior work has demonstrated that STING induction is toxic to T cells; however, natural killer (NK) cells are unaffected, due to their differential regulation of autophagy. Here we investigate the immunomodulatory properties of STING agonism alone and in combination with NK cells using short-term microfluidic culture of fresh patient-derived organotypic tumor spheroids (PDOTS). Methods: Surgical cases from Brigham and Women’s Hospital under an IRB-approved protocol were studied. PDOTS were generated as previously described. Ex vivo response was assessed by fluorescent live/dead imaging, immunofluorescence (IF), multiplexed cytokine array, and single cell RNA sequencing (scRNAseq). Baseline immune phenotypes were analyzed by FACS from single cells isolated during tumor sample preparation. Results: Twelve explants were studied. Two specimens were excluded from viability assessment due to excess of fibrotic material and low viability. Using a cut-off of -40%, three cases were characterized as responders (R) and seven as non-responders (NR). We observed significant induction of CXCL10 in all samples treated with STING agonist. IFN-β, IFN-γ, TNF-α, and MIP1-α were also consistently induced by STING agonist treatment. More detailed analysis of two samples by scRNAseq revealed a strong interferon stimulated genes (ISG) signature in STING agonist conditions; the cellular source of CXCL10 secretion in STING agonist treatment was tumor cells and fibroblasts. We also observed profound changes in myeloid biology, indicating that these cells polarized to a more pro-inflammatory and antigen-presenting phenotype with STING agonism. Interestingly, NK-based cell therapy added to PDOTS cultures displayed better persistence and enhanced effector function relative to endogenous NK cells, with and without STING agonism. Conclusions: Using tumor explants and a variety of orthogonal techniques, we investigated the response to STING agonism and NK cellular therapy ex vivo. Our results indicate that STING agonism remodels the TME, creating a more immune-permissive environment. STING agonism induces secretion of chemoattractant CXCL10 by tumor cells and fibroblasts. STING agonism does not abrogate NK cell effector function and therefore, may synergize with NK cell therapies. Citation Format: Patrick H. Lizotte, Elena Ivanova, Sung Park, Nathaniel Spicer, Sophie Kivlehan, Iliana Gjeci, Stefan Kiesgen, Vicky Appleman, LeeAnn Talarico, Michael Y. Tolstorukov, Raphael Bueno, David A. Barbie, Cloud P. Paweletz. Combination STING agonist and NK cellular therapy in patient derived organotypic tumor spheroids [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5235.

Effect of Intrinsic STING of CD8+T Cells on Self-Metabolic Reprogramming and Anti-Tumor Effects.

495P Intrinsic STING of CD8+T Cells Regulates Self-Metabolic Reprogramming and Exerts Anti-Tumor Effects

STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

Cgas-Sting–mediated DNA Sensing Maintains CD8 + T Cell Stemness and Promotes Antitumor T Cell Therapy

STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity

Abstract 6644: A Comprehensive in Vitro and in Vivo System to Evaluate STING Agonist Efficacy in Cancer Therapeutics

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Systemic Administration of STING Agonist Promotes Myeloid Cells Maturation and Antitumor Immunity Through Regulating Hematopoietic Stem and Progenitor Cell Fate

STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function

Abstract 5235: Combination STING agonist and NK cellular therapy in patient derived organotypic tumor spheroids

CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of TH1 and TH9 cells

Immunogenicity of Small‐cell Lung Cancer Associates with STING Pathway Activation and is Enhanced by ATR and TOP1 Inhibition

Targeting STING signaling for the optimal cancer immunotherapy

Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies

Abstract 6598: Inhibition of cGAS as a strategy to restore anti-tumor immunity response to STING agonist in chromosomally unstable tumors

Glycolysis drives STING signaling to facilitate dendritic cell antitumor function

Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy

Data from MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.

STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade